Cite
HARVARD Citation
Danese, S. et al. (2022). Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial. Lancet gastroenterology and hepatology. pp. 294-306. [Online].